Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jan 05, 2022 |
referred to health |
Feb 19, 2021 |
print number 4585a |
Feb 19, 2021 |
amend and recommit to health |
Feb 04, 2021 |
referred to health |
Assembly Bill A4585A
2021-2022 Legislative Session
Sponsored By
RAJKUMAR
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Bill Amendments
co-Sponsors
Charles Lavine
Deborah Glick
Rodneyse Bichotte Hermelyn
David Weprin
2021-A4585 - Details
- Current Committee:
- Assembly Health
- Law Section:
- Public Health Law
- Laws Affected:
- Ren §2182 to be §2183, add §2182, Pub Health L
2021-A4585 - Summary
Requires health care providers to inform eligible patients who have tested positive and who are at high risk of severe illness from COVID-19 of the option for monoclonal antibody treatment and to administer such therapy or assist the patient in obtaining the treatment from another provider.
2021-A4585 - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4585 2021-2022 Regular Sessions I N A S S E M B L Y February 4, 2021 ___________ Introduced by M. of A. RAJKUMAR, ANDERSON, GLICK, WEPRIN, NOLAN, SEPTI- MO, HEVESI, GALEF, EICHENSTEIN, BICHOTTE HERMELYN, BRAUNSTEIN, LAVINE -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to administration of the monoclonal antibody treatment for high risk patients suffering from COVID-19 THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Short title. This act shall be known and may be cited as the "COVID-19 Early Intervention Act". § 2. Legislative intent. Monoclonal antibody treatment has been shown to prevent people at high risk of severe COVID-19 disease from hospi- talization or death if the treatment is administered within 10 days of the patient showing symptoms. Even though this FDA-approved treatment is shown to be life-saving, the treatment is often unused by health care providers. Drug manufacturer Eli Lilly released a study indicating that the treatment decreased the rate of hospitalizations and death by 70%. The intent of this legislation is to require hospitals and other health providers to inform high risk patients of the availability of the mono- clonal antibody treatment and to administer it to consenting patients where supplies exist. This can include treatment by any drug company that manufactures the monoclonal antibody treatment, including but not limited to Eli Lily or Regeneron. § 3. Section 2182 of the public health law is renumbered section 2183 and a new section 2182 is added to read as follows: § 2182. MONOCLONAL ANTIBODY TREATMENT. 1. HOSPITALS AND HEALTH CARE PROVIDERS SHALL BE REQUIRED TO INFORM PATIENTS AT HIGH RISK OF HOSPITAL- IZATION OR SEVERE ILLNESS DUE TO COVID-19 OF THE OPTION OF MONOCLONAL ANTIBODY TREATMENT WHERE SUCH PATIENT HAS TESTED POSITIVE FOR COVID-19 AND WHERE SUCH TREATMENT IS MEDICALLY APPROPRIATE. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD09121-04-1
co-Sponsors
Charles Lavine
Deborah Glick
Rodneyse Bichotte Hermelyn
David Weprin
2021-A4585A (ACTIVE) - Details
- Current Committee:
- Assembly Health
- Law Section:
- Public Health Law
- Laws Affected:
- Ren §2182 to be §2183, add §2182, Pub Health L
2021-A4585A (ACTIVE) - Summary
Requires health care providers to inform eligible patients who have tested positive and who are at high risk of severe illness from COVID-19 of the option for monoclonal antibody treatment and to administer such therapy or assist the patient in obtaining the treatment from another provider.
2021-A4585A (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 4585--A 2021-2022 Regular Sessions I N A S S E M B L Y February 4, 2021 ___________ Introduced by M. of A. RAJKUMAR, LAVINE, GLICK, BICHOTTE HERMELYN, WEPRIN, NOLAN, EICHENSTEIN, HEVESI, SEPTIMO, ANDERSON, BRAUNSTEIN, GALEF, GALLAGHER, COOK, CYMBROWITZ, SEAWRIGHT, FORREST, MAGNARELLI, DILAN -- read once and referred to the Committee on Health -- commit- tee discharged, bill amended, ordered reprinted as amended and recom- mitted to said committee AN ACT to amend the public health law, in relation to administration of the monoclonal antibody treatment for high risk patients suffering from COVID-19 THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Short title. This act shall be known and may be cited as the "COVID-19 Early Intervention Act". § 2. Legislative intent. Monoclonal antibody treatment has been shown to prevent people at high risk of severe COVID-19 disease from hospi- talization or death if the treatment is administered within 10 days of the patient showing symptoms. Even though this FDA-approved treatment is shown to be life-saving, the treatment is often unused by health care providers. Drug manufacturer Eli Lilly released a study indicating that the treatment decreased the rate of hospitalizations and death by 70%. The intent of this legislation is to require hospitals and other health providers to inform high risk patients of the availability of the mono- clonal antibody treatment and to administer it to consenting patients where supplies exist. This can include treatment by any drug company that manufactures the monoclonal antibody treatment, including but not limited to Eli Lily or Regeneron. § 3. Section 2182 of the public health law is renumbered section 2183 and a new section 2182 is added to read as follows: § 2182. MONOCLONAL ANTIBODY TREATMENT. 1. HOSPITALS AND HEALTH CARE PROVIDERS SHALL BE REQUIRED TO INFORM PATIENTS AT HIGH RISK OF HOSPITAL- IZATION OR SEVERE ILLNESS DUE TO COVID-19 OF THE OPTION OF MONOCLONAL EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.